Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00069745
Other study ID # GPC SAT3-03-01
Secondary ID
Status Completed
Phase Phase 3
First received September 30, 2003
Last updated August 1, 2012
Start date September 2003
Est. completion date March 2007

Study information

Verified date August 2012
Source Agennix
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

PURPOSE:

The SPARC trial is designed to compare the combination of the investigational oral cytotoxic drug, satraplatin, and prednisone, versus prednisone alone as second line chemotherapy in patients with hormone-refractory prostate cancer (HRPC).

TARGET PATIENT POPULATION:

The SPARC trial is intended for patients who have hormone-refractory prostate cancer (HRPC) and whose disease has progressed after treatment with one chemotherapy regimen. Please refer to the Eligibility Criteria page for the key inclusion and exclusion criteria.

WHAT IS SATRAPLATIN:

Satraplatin is a member of the platinum-based class of chemotherapy drugs. Platinum-based drugs have been clinically proven to be one of the most effective classes of anticancer therapies. Unlike the currently marketed platinum-based drugs, satraplatin can be given orally. Satraplatin is also the only platinum-based drug that has demonstrated efficacy against prostate cancer in a randomized trial.

RATIONALE:

There are currently no approved chemotherapy drugs for the second line treatment of hormone-refractory prostate cancer (HRPC). In a preliminary randomized trial conducted in Europe, the combination of satraplatin and prednisone had superior activity compared to prednisone alone, for the treatment of HRPC patients who had not previously been treated with chemotherapy


Recruitment information / eligibility

Status Completed
Enrollment 0
Est. completion date March 2007
Est. primary completion date January 2006
Accepts healthy volunteers No
Gender Male
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Stage D2 metastatic prostate cancer

- Progression after one prior chemotherapy

- ECOG Performance status equal / less than 2

- Life expectancy > 3 months

- Surgical or medical castration

- Adequate bone marrow, hepatic and renal functions

- Informed consent

Exclusion Criteria:

- More than one prior chemotherapy

- Prior platinum containing compounds

- Prior malignancy

- Prior significant RT/radionuclide therapy

- Major GI surgery or GI disease affecting absorption

- Disease with contraindication to steroids

- Brain metastases

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Satraplatin

Prednisone


Locations

Country Name City State
Argentina Hospital Italiano Regional del Sur Dept. Oncology Bahia Blanca
Argentina Grupo Plaza Dept. Oncology Belen de Escobar
Argentina Instituto Alexander Fleming Buenos Aires
Argentina Instituto Quirúrgico del Callao Buenos Aires
Argentina Clinica Oncologica de Excelencia Capital Federal Buenos Aires
Argentina Hospital General de Agudos E. Tornu Capital Federal Buenos Aires
Argentina Hospital Italiano de Buenos Aires Capital Federal Buenos Aires
Argentina Policlinica Bancaria "9 de Julio" Av. Gaona 2197 Capital Federal Buenos Aires
Argentina Centro Oncológico LALCEC Concepcion del Uruguay, Entre Ríos
Argentina Hospital Italiano de Cordoba Dept. Oncology Cordoba
Argentina Unidad Oncologica del Neuquen Neuquen
Argentina Salisbury Investigaciones Clinicas del Grupo CER S.A. Quilmes Buenos Aires
Argentina Caici Dept. Oncology Rosario
Argentina Centro Oncologico Rosario Rosario
Argentina Centro San Roque San Miguel de Tucumán, Tucumán
Argentina Clinical Especializada ISIS Santa Fe
Belgium AZ-VUB Bruxelles
Belgium Hopital Erasme Bruxelles
Belgium Institut Jules Bordet Service de Chimiothérapie Bruxelles
Belgium UCLC St. Luc Bruxelles
Belgium Sint Maartenziekenhuis Kortrijk
Croatia Clinical Hospital Split Department of Oncology and Radiotherapy Split
Croatia Clinical Hostpital Rebro Department of Oncology Zagreb
France Institut Bergonié Bordeaux Cedex
France Centre Georges François Leclerc Dijon
France Clinique du Mail Service d'Oncologie Grenoble
France Hôpital de La Tronche - CHU de Grenoble: Departement de cacerologie et d'hematologie Grenoble Cedex 09
France Centre Hospitalier Départemental La Roche Sur Yon
France CHU de Bicêtre Le Kremlin Bicetre
France Chu Dupuytren Limoges
France CRLC Léon Bérard Lyon
France Centre Hospitalier Belfort-Montbeliard Montbeliard
France CRLC Val d'Aurelle Paul-Lamarque Montpellier
France Centre Antoine Lacassagne Oncologie medicale Nice Cedex 2
France Hôpital Saint-Louis: Service de Radiotherapy Paris
France Hôpital Tenon Paris
France CHU de Poitiers Poitiers
France Institut Jean , Service d'Oncologie Reims
France Centre Eugene Marquis Rennes Cedex
France Centre Alexis Vautrin Vandoeuvre Les Nancy
Germany RWTH Aachen Aachen
Germany Fach- und Belegarzte fur Urologie Berlin
Germany Vivantes Krankenhaus am Urban Berlin
Germany Diakonissenkrankenhaus Dessau gGmbH Dessau
Germany Universitätsklinikum der Carl-Gustav-Carus Universität Dresden
Germany Stadtische Klinicen Frankfurt a.M. Hochst Frankfurt a.M. Hochst
Germany EuromedClinic Fürth
Germany Klinikum der medizinischen Fakultät der Martin-Luther-Universität Halle-Wittenberg Halle
Germany Niedergelassener Urologe Hamburg
Germany Medizinische Hochschule Hannover
Germany Marienhospital II Herne
Germany Universitatklinikum Schleswig-Holstein Lubeck
Germany Klinickum der Johannes-Gutenberg Universitat Mainz
Germany Klinikum der Philipps - Universitat Marburg Marburg
Germany Klinikum rechts der Isar München
Germany Universitatklinikum Munster Munster
Germany Klinik Bad Trissel Oberaudorf
Germany Urologische Praxis Saarbrücken
Hungary National Institute of Oncology Budapest
Hungary St. Istvan Hospital Budapest
Hungary St. Margit Hospital Budapest
Hungary Pecs Medical University Pecs
Israel Soroka Medical Center Beerhseva
Israel Rambam Medical Center Haifa
Israel Hadassah University Jerusalem
Israel Hospital Ein Kerem Asaf Harofeh Medical Center Zerifin
Italy Istituto Nazionale per la Ricerca sul Cancro (IST) Genoa
Italy Universita degli Studi di Napoli Federico II-Nuovo Policlinico Napoli
Italy A.S.O. San Luigi Orbassano
Italy Azienda Ospedaliera di Padova Padova
Italy A.O. San Camillo-Forlanini Rome
Italy Istituto Clinico Humanitas: Dipartimento di Oncologia Medica ed Ematologia Rozanno (MI)
Netherlands Academic Hospital of the University of Amsterdam Amsterdam
Netherlands Academisch Ziekenhuis Nijmegen: Urology Department Nijmegen
Netherlands Streekziekenhuis Koningin : Dept. Urology Winterswijk
Peru Essalud Dept. Oncology Jesus Maria
Peru INEN Dept Onco-Hemato Lima
Peru San Felipe (Oncomedical) Lima
Poland Oddzial Chemioterapii, Bialostocki Osrodek Onkologiczny Bialystok
Poland Oddzial Onkologii I Radioterapii, Szpital Morski im. PCK Gdynia
Poland Akademia Medyczna w Lodzi Lodz
Poland Akademia Medyczna w Lublinie Lublin
Poland Oddzial Radioterapii, Wielkopolskie Centrum Onkologii - Instytut Poznan
Poland Akademia Medyczna w Szczecinie Szczecin
Poland Klinika Nowotworow Ukladu Moczowego, Centrum Onkologii - Instytut Warszawa
Poland Oddzial Chemioterapii, 4 Wojskowy Szpital Kliniczny Wroclaw
Russian Federation Hertzen Research Institute of Oncology Moscow
Russian Federation N.N Blokchin Cancer Research Centre Moscow
Russian Federation Medical Radilogical Research Center of Rams Obninsk
Spain Hospital Clinic i Provincial, Sevicio de Oncología Médica Barcelona
Spain Hospital de la Santa Creu i Sant Pau, Sevicio de Oncología Médica Barcelona
Spain Hospital Clínico San Carlos, Sevicio de Oncología Médica Madrid
Spain Hospital Ramon y Cajal Madrid
Spain Clinica Universitaria de Navarra, Sevicio de Oncología Médica Pamplona
Spain Hospital Universitario Marqués de Valdecilla, Sevicio de Oncología Médica Santander
Spain Instituto Valenciano de Oncología: Sevicio de Oncología Médica Valencia
United Kingdom Aberdeen Royal Infirmary Aberdeen
United Kingdom CRUK Institute for Cancer Studies Birmingham
United Kingdom Bristol Oncology Centre Bristol
United Kingdom Beatson Oncology Center Glasgow
United Kingdom Guy's hospital London
United Kingdom St George's Healthcare Dept of Oncology, Tooting London
United Kingdom St. Bartholomew's Hospital Dept. of Medical Oncology London
United Kingdom Northern Centre for Cancer Treatment Newcastle Upon Tyne
United Kingdom Lister Hospital Department of Urology Stevenage Hertfordshire
United Kingdom Royal Marsden Hospital Sutton
United States Texas Cancer Center Abilene Texas
United States Albany Regional Cancer Center Albany New York
United States New York Oncology Hematology, P.C. Albany New York
United States Hematology Oncology Associates Albuquerque New Mexico
United States Lovelace Sandia Health Systems Albuquerque New Mexico
United States The University of New Mexico Albuquerque New Mexico
United States Veterans Affairs Medical Center Albuquerque New Mexico
United States Cancer Centers of Florida-Altamonte Altamonte Springs Florida
United States Texas Oncology Arlington Texas
United States Advanced Oncology Associates Armonk New York
United States Southwest Regional Cancer Center Austin Texas
United States Texas Oncology Cancer Center Austin Texas
United States Mamie McFaddin Ward Cancer Center Beaumont Texas
United States Texas Onoclogy PA - Bedford Bedford Texas
United States Birmingham Hematology and Oncology Birmingham Alabama
United States Birmingham Hematology and Oncology Birmingham Alabama
United States The Center for Hematology Oncology Boca Raton Florida
United States Roswell Park Cancer Institute Buffalo New York
United States Interlakes Oncology Hematology Canandaigua New York
United States Raleigh Hematology Oncology Clinic Cary North Carolina
United States Oncology Associates of Cedar Rapids Cedar Rapids Iowa
United States Charleston Cancer Center Charleston South Carolina
United States Medical University of South Carolina Hollings Cancer Center Charleston South Carolina
United States Missouri Cancer Associates Columbia Missouri
United States Texas Cancer Center at Medical City Dallas Texas
United States Texas Oncology, P.A. Dallas Texas
United States The Texas Cancer Center Dallas Texas
United States TOPA Sammons Cancer Center Dallas Texas
United States Decatur Memorial Hospital Decatur Illinois
United States Texas Cancer Center Denton Texas
United States Rocky Mountain Cancer Center - Midtown Denver Colorado
United States Karmanos Cancer Institute, Wayne State University Detroit Michigan
United States Hematology and Oncology Associates of Northeastern PA / PC Dunmore Pennsylvania
United States Puget Sound Cancer Center - Edmonds Edmonds Washington
United States El Paso Cancer Treatment Center El Paso Texas
United States Willamette Valley Cancer Center Eugene Oregon
United States Central Indiana Cancer Centers Fishers Indiana
United States San Antonio Tumor & Blood Clinic Fredericksburg Texas
United States California Cancer Center Fresno California
United States Texas Oncology, P.A. Ft. Worth Texas
United States Texas Oncology, P.A. Garland Texas
United States Hartford Hospital Hartford Connecticut
United States New Hampshire Oncology-Hematology PA Hooksett New Hampshire
United States Central Indiana Cancer Centers Indianapolis Indiana
United States Indiana Hematology Oncology Consultants Indianapolis Indiana
United States Texas Oncology, P.A. - Irving Irving Texas
United States Capitol Comprehensive Cancer Care Clinic Jefferson City Missouri
United States Dayton Oncology Hematology Kettering Ohio
United States Louisiana Oncology Associates Lafayette Louisiana
United States Comprehensive Cancer Centers of Nevada Las Vegas Nevada
United States Nevada Cancer Institute Las Vegas Nevada
United States Lake Vista Cancer Center Lewisville Texas
United States Pacific Shores Medical Group Long Beach California
United States Longview Cancer Center Longview Texas
United States Division of Hematology - Oncology Los Angeles California
United States DeQuattro Community Cancer Center Manchester Connecticut
United States Maplewood Cancer Center Maplewood Minnesota
United States S. Texas Cancer Center McAllen Texas
United States The West Clinic Memphis Tennessee
United States Texas Cancer Center of Mesquite Mesquite Texas
United States Hematology/Oncology Group of South Florida Miami Florida
United States Innovative Medical Research of South Florida Miami Shores Florida
United States Allison Cancer Center Midland Texas
United States Froedtert Memorial Lutheran Hospital Milwaukee Wisconsin
United States Virginia Piper Cancer Institute Minneapolis Minnesota
United States LSU Health Science Center, Stanley S. Scott Cancer Center New Orleans Louisiana
United States Florida Cancer Institute New Port Richey Florida
United States Columbia Presbyterian Medical Center New York New York
United States Northwest Medical Specialists Niles Illinois
United States Virginia Oncology Associates Norfolk Virginia
United States Ocala Oncology Center Ocala Florida
United States West Texas Cancer Center Odessa Texas
United States Cancer Care Associates Oklahoma City Oklahoma
United States Nebraska Methodist Hospital Cancer Center Omaha Nebraska
United States Kansas City Cancer Centers - Southwest Overland Park Kansas
United States University of Pennsylvania Abramson Cancer Center Philadelphia Pennsylvania
United States Hematology Oncology Associates Phoenix Arizona
United States University of Pittsburgh Cancer Institute- Hillman Cancer Center Pittsburgh Pennsylvania
United States Berkshire Hematology Oncology Pittsfield Massachusetts
United States South Florida Oncology & Hematology Plantation Florida
United States Hematology/Oncology Associates of Treasure Coast Port St. Lucie Florida
United States New York Oncology Hematology Rexford New York
United States University of California Davis Cancer Center, Division of Hematology-Oncology Sacramento California
United States Onc and Hem Associates of SW VA, Inc. Salem Virginia
United States Hematology Oncology Associates of South Texas San Antonio Texas
United States Sharp Healthcare - Clinical Oncology Research San Diego California
United States New Mexico Cancer Care Associates Santa Fe New Mexico
United States Maine Center for Cancer Medicine & Blood Disorders Scarborough Maine
United States Northern AZ Hematology & Oncology Assoc. Sedona Arizona
United States Cancer Center of the Carolinas, Seneca Seneca South Carolina
United States North Shore Research Association Skokie Illinois
United States Cancer Care Northwest-North Spokane Washington
United States St. Joseph Oncology, Inc. St. Joseph Missouri
United States Hematology/Oncology Consultants, Inc. St. Louis Missouri
United States VA Medical Center Syracuse Syracuse New York
United States Oncology and Hematology Associates of West Broward P.A. Tamarac Florida
United States Hematology Oncology Physicians/SMO Tucson Arizona
United States Cancer Care Associates Tulsa Oklahoma
United States Arizona Cancer Center Tuscon Arizona
United States Tyler Cancer Center Tyler Texas
United States Northwest Cancer Specialists Vancouver Washington
United States Waco Cancer Care Research Center Waco Texas
United States Arch Medical Services, Inc. Washington Missouri
United States Texas Oncology, P.A. - Deke Slayton Cancer Center Webster Texas
United States Piedmont Hematology - Oncology Winston - Salem North Carolina

Sponsors (1)

Lead Sponsor Collaborator
Agennix

Countries where clinical trial is conducted

United States,  Argentina,  Belgium,  Croatia,  France,  Germany,  Hungary,  Israel,  Italy,  Netherlands,  Peru,  Poland,  Russian Federation,  Spain,  United Kingdom, 

See also
  Status Clinical Trial Phase
Recruiting NCT05540392 - An Acupuncture Study for Prostate Cancer Survivors With Urinary Issues Phase 1/Phase 2
Recruiting NCT05613023 - A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT Phase 3
Recruiting NCT05156424 - A Comparison of Aerobic and Resistance Exercise to Counteract Treatment Side Effects in Men With Prostate Cancer Phase 1/Phase 2
Completed NCT03177759 - Living With Prostate Cancer (LPC)
Completed NCT01331083 - A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer Phase 2
Recruiting NCT05540782 - A Study of Cognitive Health in Survivors of Prostate Cancer
Active, not recruiting NCT04742361 - Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer Phase 3
Completed NCT04400656 - PROState Pathway Embedded Comparative Trial
Completed NCT02282644 - Individual Phenotype Analysis in Patients With Castration-Resistant Prostate Cancer With CellSearch® and Flow Cytometry N/A
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT06305832 - Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer Phase 2
Recruiting NCT05761093 - Patient and Physician Benefit/ Risk Preferences for Treatment of mPC in Hong Kong: a Discrete Choice Experiment
Completed NCT04838626 - Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection Phase 2/Phase 3
Recruiting NCT03101176 - Multiparametric Ultrasound Imaging in Prostate Cancer N/A
Completed NCT03290417 - Correlative Analysis of the Genomics of Vitamin D and Omega-3 Fatty Acid Intake in Prostate Cancer N/A
Completed NCT00341939 - Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
Completed NCT01497925 - Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer Phase 1
Recruiting NCT03679819 - Single-center Trial for the Validation of High-resolution Transrectal Ultrasound (Exact Imaging Scanner ExactVu) for the Detection of Prostate Cancer
Completed NCT03554317 - COMbination of Bipolar Androgen Therapy and Nivolumab Phase 2
Completed NCT03271502 - Effect of Anesthesia on Optic Nerve Sheath Diameter in Patients Undergoing Robot-assisted Laparoscopic Prostatectomy N/A